首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1078232

脆弱性X症候群(Fxs)治疗的全球市场(2022年～2029年)

Global Fragile X Syndrome (Fxs) Treatment Market - 2022-2029

出版日期: 2022年05月25日 | 出版商:

DataM Intelligence | 英文 185 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告提供全球脆弱性X症候群(Fxs)治疗市场调查，提供市场概要，市场规模和预测，趋势，成长要素及课题，客户形势，类型·适应症类型·终端用户·各地区的分析，新企业简介等资讯。

简介
- 各地区的市场规模分析(2020年～2029年，及2021年～2029年)
- 各地区的市场魅力指数
北美
- 简介
- 主要地区具体动态
- 各类型的市场规模分析，及与前一年同期比较成长分析
- 各适应症类型的市场规模分析，及与前一年同期比较成长分析
- 各终端用户的市场规模分析，及与前一年同期比较成长分析
- 各国市场规模分析，及与前一年同期比较成长分析
欧洲
- 简介
- 主要地区具体动态
- 各类型的市场规模分析，及与前一年同期比较成长分析
- 各适应症类型的市场规模分析，及与前一年同期比较成长分析
- 各终端用户的市场规模分析，及与前一年同期比较成长分析
- 各国市场规模分析，及与前一年同期比较成长分析
南美
- 简介
- 主要地区具体动态
- 各类型的市场规模分析，及与前一年同期比较成长分析
- 各适应症类型的市场规模分析，及与前一年同期比较成长分析
- 各终端用户的市场规模分析，及与前一年同期比较成长分析
- 各国市场规模分析，及与前一年同期比较成长分析
亚太地区
- 简介
- 主要地区具体动态
- 各类型的市场规模分析，及与前一年同期比较成长分析
- 各适应症类型的市场规模分析，及与前一年同期比较成长分析
- 各终端用户的市场规模分析，及与前一年同期比较成长分析
- 各国市场规模分析，及与前一年同期比较成长分析
中东和非洲
- 简介
- 主要地区具体动态
- 各类型的市场规模分析，及与前一年同期比较成长分析
- 各适应症类型的市场规模分析，及与前一年同期比较成长分析
- 各终端用户的市场规模分析，及与前一年同期比较成长分析

第11章 X染色体脆折症候群(Fxs)治疗市场:竞争情形

主要的发展与策略
企业占有率分析
产品的基准

第12章 X染色体脆折症候群(Fxs)治疗市场:企业简介概要

Ovid Therapeutics
- 企业概要
- 产品系列·种类
- 主要亮点
- 财务概要
Tetra Therapeutics
Neuren Pharmaceuticals
Anavex Life Sciences Corp
Confluence Pharmaceuticals
Zynerba Pharmaceuticals, Inc.

第13章 X染色体脆折症候群(Fxs)治疗市场:DataM

附录
关于本公司·服务
咨询方式

简介目录

Product Code: DMOT5152

Market Overview

The global fragile x syndrome (fxs) treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Market Dynamics

The factors influencing the global fragile x syndrome (fxs) treatment market are the increasing research for effective treatment and the growing prevalence of fragile x syndrome (fxs).

The increasing research for effective treatment is expected to drive the market growth in the forecast period

FXS (Fragile X Syndrome) is a genetic condition. FXS is caused by mutations in the FMR1 gene, which scientists first discovered. The FMR1 gene usually produces the FMRP protein. FMRP is required for the development of the brain. People with FXS do not produce this protein. Other fragile X-associated disorders cause changes in the FMR1 gene, but most people produce some of the protein. Fragile X and its associated conditions, such as Fragile X-associated Primary Ovarian Insufficiency (FXPOI) and Fragile X-Associated Tremor/Ataxia Syndrome, as well as their diagnosis, treatment, management, prevention, and inheritance, are funded and researched by the National Institute of Child Health and Human Development (NICHD) (FXTAS). All three conditions are caused by changes in the same gene on the X chromosome.

Moreover, the Fragile X Research Foundation is working to find specific treatments and, eventually, a cure, but there is currently no cure. Fragile X syndrome affects most males and many females throughout their lives. The cost of treatment, special education, and lost income to society are enormous. The need for treatment-oriented research is critical.

Limited treatment options are expected to hamper the market growth

Although there is no cure for Fragile X syndrome, there are treatments that can help to alleviate its symptoms. Individuals with Fragile X who receive the proper education, therapy, and medications have the best chance of using all of their abilities and skills. Due to the limited treatment options, market growth is expected to be hampered.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted health systems' ability to continue providing essential health services. While increasing demand for COVID-19 care is putting pressure on health systems worldwide, it is critical to maintain preventive and curative services, especially for the most vulnerable populations, such as children, the elderly, people with chronic illnesses, minorities, and people with disabilities.

Moreover, infection with SARS-CoV-2 causes the release of inflammatory cytokines, which can cause an overabundance of inflammatory cytokines, leading to a cytokine storm and a worsening prognosis. Several signaling pathways, including the PI3K/Akt/mTOR and Ras/MAPK/ERK cascades, GSK-3 kinase, and NF-kB, are involved in these processes. In fragile X syndrome (FXS), the most common cause of inherited mental retardation and the most common genetic form of autism spectrum disorder, those signaling pathways, as well as IGF-1, are upregulated, leading to an increase in metalloproteinase 9 (MMP-9) levels, tissue damage, a pro-inflammatory state, and disruption of the blood-brain barrier. FXS and COVID-19 have so many links that suggest that they share pathophysiological mechanisms. FXS would be a significant risk factor for developing a severe form of COVID-19, and SARS-CoV-2 could exacerbate the symptoms and prognosis of both FXS patients and asymptomatic Fmr1 premutation carriers. This is expected to rise demand for the Fragile X Syndrome (Fxs) treatment. Hence, covid-19 is expected to have an impact on market growth.

Segment Analysis

Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) segment is expected to dominate the market growth

FXTAS (Fragile X-associated tremor/ataxia syndrome) is characterized by movement and thinking difficulties (cognition). FXTAS is a late-onset disorder that usually manifests after 50, and the signs and symptoms worsen as the patient gets older. Males are affected more frequently and severely than females by this condition. Damage to the cerebellum, the part of the brain that controls movement, and white matter, a type of brain tissue, can be seen with magnetic resonance imaging in those who are affected (MRI). FXTAS is characterized by movement problems and other impairments resulting from this damage.

Some people with FXTAS have issues with the autonomic nervous system, which controls involuntary body functions, resulting in bladder or bowel control issues. Cognitive impairments are common in people with FXTAS. They may experience short-term memory loss and executive function impairment, which is the ability to plan and carry out actions and develop problem-solving strategies. Impulse control, self-monitoring, appropriately focusing attention, and cognitive flexibility are all harmed when this function is lost. Anxiety, depression, moodiness, and irritability are common symptoms of FXTAS.

Geographical Analysis

North America region is expected to hold the largest market share in the global fragile x syndrome (Fxs) treatment market

The growing prevalence of fragile x syndrome (Fxs) and better R&D in this region is expected to drive the market growth.

In the United States, studies estimate that 1 in 148 to 1 in 291 females and 1 in 290 to 1 in 855 males have a fragile X premutation. Moreover, fragile X syndrome affects about 1 in 2500-4000 males and 1 in 7000-8000 females. Female carrier status is estimated to affect one in every 130-250 people, while male carrier status affects one in every 250-800 people. Hence, with the growing prevalence of the disease in this region the market is expected to grow.

Competitive Landscape

With mergers, acquisitions, and product launches, the global fragile x syndrome (Fxs) treatment market is moderately competitive. Some of the key players in the market are Ovid Therapeutics., Tetra Therapeutics, Neuren Pharmaceuticals, Anavex Life Sciences Corp., Confluence Pharmaceuticals, Zynerba Pharmaceuticals, Inc.

Ovid Therapeutics

Overview: Ovid Therapeutics is a biotech company based in New York that develops medicines for people with rare neurological disorders using its BoldMedicine approach.

Product Portfolio: The company's OV101 (gaboxadol) is in clinical studies used in males aged 13 to 22 to treat Fragile X syndrome. A three-arm, double-blind clinical trial is evaluating the safety and tolerability of OV101 in Fragile X syndrome-affected adolescent and young adult males aged 13 to 22 years old.

Why Purchase the Report?

Visualize the composition of the global fragile x syndrome (Fxs) treatment market segmentation by type, indication type, andend user, highlighting the key commercial assets and players.

identify commercial opportunities in global fragile x syndrome (Fxs) treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global fragile x syndrome (Fxs) treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global fragile x syndrome (Fxs) treatment market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

1. Fragile X Syndrome (Fxs) Treatment Market Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Fragile X Syndrome (Fxs) Treatment Market- Market Definition and Overview

3. Fragile X Syndrome (Fxs) Treatment Market- Executive Summary

3.1. Market Snippet By Type
3.2. Market Snippet By Indication Type
3.3. Market Snippet By End User
3.4. Market Snippet By Region

4. Fragile X Syndrome (Fxs) Treatment Market-Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers:
  - 4.1.1.1. The increasing research for effective treatment
- 4.1.2. Restraints:
  - 4.1.2.1. Limited treatment options
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Fragile X Syndrome (Fxs) Treatment Market- Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs

6. Fragile X Syndrome (Fxs) Treatment Market- COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. Fragile X Syndrome (Fxs) Treatment Market- By Type

7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
7.3. Market Attractiveness Index, By Type
- 7.3.1. Drugs
  - 7.3.1.1.1. Introduction
  - 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 7.3.2. Physical therapy
- 7.3.3. Others

8. Fragile X Syndrome (Fxs) Treatment Market-By Indication Type

8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
8.3. Market Attractiveness Index, By Indication Type
- 8.3.1. Fragile X-Associated Tremor/Ataxia Syndrome
  - 8.3.1.1.1. Introduction
  - 8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 8.3.2. Fragile X-Associated Primary Ovarian Insufficiency

9. Fragile X Syndrome (Fxs) Treatment Market- By End User

9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Specialty Clinics
9.4. Other

10. Fragile X Syndrome (Fxs) Treatment Market- By Region

10.1. Introduction
- 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
- 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
- 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
- 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
- 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
- 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Fragile X Syndrome (Fxs) Treatment Market- Competitive Landscape

11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking

12. Fragile X Syndrome (Fxs) Treatment Market- Company Profiles

12.1. Ovid Therapeutics*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Key Highlights
- 12.1.4. Financial Overview
12.2. Tetra Therapeutics
12.3. Neuren Pharmaceuticals
12.4. Anavex Life Sciences Corp
12.5. Confluence Pharmaceuticals
12.6. Zynerba Pharmaceuticals, Inc.

LIST NOT EXHAUSTIVE

13. Fragile X Syndrome (Fxs) Treatment Market- DataM

13.1. Appendix
13.2. About Us and Services
13.3. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

FAQ